

#3

POWER OF ATTORNEY

On behalf of National Jewish Center for Immunology and Respiratory Medicine, a Colorado non-profit corporation having a principal place of business at 1400 Jackson Street, Denver, Colorado 80206, being the assignee of and owning all right, title and interest in the invention entitled "NOVEL EMBRYONIC CELL POPULATIONS AND METHODS TO ISOLATE SUCH POPULATIONS, for which application for Letters Patent of the United States has been made by the inventors, Gordon A. Keller, Marion Kennedy, Kyunghee Choi and Meri T. Firpo, said application having been filed on November 21, 1994, receiving Serial No. 08/343,686, and further identified as Attorney File No. 2879-26, I, Frederick A. Langille, Executive Vice President and Chief Operating Officer of National Jewish Center for Immunology and Respiratory Medicine, hereby appoint Michael D. McIntosh, Registration No. 26,305; David F. Zinger, Registration No. 29,127; Thomas R. Marsh, Registration No. 31,039; Craig C. Groseth, Registration No. 31,713; Michael L. Tompkins, Registration No. 30,980; Christopher J. Kulish, Registration No. 33,056, Sabrina C. Stavish, Registration No. 33,374; Todd P. Blakely, Registration No. 31,328, James L. Johnson, Registration No. 34,193; Lewis D. Hansen, Registration No. 35,536; Joseph E. Kovarik, Registration No. 33,005; Kent A. Fischmann, Registration No. 35,511; Gary J. Connell, Registration No. 32,020; David F. Dockery, Registration No. 34,323; John R. Posthumus, Registration No. 36,245; Ross E. Breyfogle, Registration No. 36,759; Mark H. Snyder, Registration No. 37,239; Carol Talkington Verser, Registration No. 37,459; Douglas W. Swartz, Registration No. 37,739; and John C. Scott, Registration No. 38,613, of SHERIDAN ROSS & MCINTOSH, 1700 Lincoln Street, Suite 3500, Denver, Colorado 80203, telephone number (303) 863-9700, as attorneys and agents for National Jewish Center for Immunology and Respiratory Medicine, with full powers of substitution, association and revocation to prosecute the application and related U.S. and foreign applications and to transact all business in the United States Patent and Trademark Office and all foreign and international patent offices connected therewith.

By: Frederick A. Langille
Frederick A. Langille
Executive Vice President
and Chief Operating Officer

Date: 2-15-95